Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2006 2
2007 7
2008 2
2009 1
2011 1
2012 3
2013 2
2015 1
2017 1
2018 1
2019 4
2020 4
2021 1
2022 3
2023 4
2024 5
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA; SUMMIT Trial Study Group. Packer M, et al. Among authors: weerakkody gj. N Engl J Med. 2025 Jan 30;392(5):427-437. doi: 10.1056/NEJMoa2410027. Epub 2024 Nov 16. N Engl J Med. 2025. PMID: 39555826 Clinical Trial.
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Nicholls SJ, Bhatt DL, Buse JB, Prato SD, Kahn SE, Lincoff AM, McGuire DK, Nauck MA, Nissen SE, Sattar N, Zinman B, Zoungas S, Basile J, Bartee A, Miller D, Nishiyama H, Pavo I, Weerakkody G, Wiese RJ, D'Alessio D; SURPASS-CVOT investigators. Nicholls SJ, et al. Among authors: weerakkody g. Am Heart J. 2024 Jan;267:1-11. doi: 10.1016/j.ahj.2023.09.007. Epub 2023 Sep 25. Am Heart J. 2024. PMID: 37758044 Free article. Clinical Trial.
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Del Prato S, et al. Among authors: weerakkody gj. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. Lancet. 2021. PMID: 34672967 Clinical Trial.
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Wiviott SD, et al. Among authors: weerakkody g. N Engl J Med. 2007 Nov 15;357(20):2001-15. doi: 10.1056/NEJMoa0706482. Epub 2007 Nov 4. N Engl J Med. 2007. PMID: 17982182 Free article. Clinical Trial.
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.
Zile MR, Borlaug BA, Kramer CM, Baum SJ, Litwin SE, Menon V, Ou Y, Weerakkody GJ, Hurt KC, Kanu C, Murakami M, Packer M; SUMMIT Trial Study Group. Zile MR, et al. Among authors: weerakkody gj. Circulation. 2025 Mar 11;151(10):656-668. doi: 10.1161/CIRCULATIONAHA.124.072679. Epub 2024 Nov 18. Circulation. 2025. PMID: 39556714 Free PMC article. Clinical Trial.
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators. Lincoff AM, et al. Among authors: weerakkody g. N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581. N Engl J Med. 2017. PMID: 28514624 Free article. Clinical Trial.
The Association Between Tirzepatide Versus Insulin Glargine and NT-proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4.
Sattar N, Weerakkody GJ, McGuire DK, Kosiborod MN, Lee MMY, Welsh P, Pearson ER, Wiese RJ, Duffin K, Wilson J, Pavo N, Hülsmann M, Pavo I. Sattar N, et al. Among authors: weerakkody gj. Circulation. 2025 May 13;151(19):1430-1432. doi: 10.1161/CIRCULATIONAHA.124.072889. Epub 2025 May 12. Circulation. 2025. PMID: 40354448 No abstract available.
40 results